TRACON Pharmaceuticals - TCON Stock Forecast, Price & News

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on TRACON Pharmaceuticals in a report on Saturday. They issued a "sell" rating for the company.

TRACON Pharmaceuticals Stock Down 1.1 %

TRACON Pharmaceuticals stock traded down $0.02 during trading hours on Wednesday, reaching $1.88. 12,658 shares of the company's stock were exchanged, compared to its average volume of 97,513. The firm's 50 day simple moving average is $1.71 and its 200 day simple moving average is $2.13. TRACON Pharmaceuticals has a twelve month low of $1.24 and a twelve month high of $4.49. The firm has a market capitalization of $38.07 million, a PE ratio of -1.02 and a beta of 1.48.

TRACON Pharmaceuticals (NASDAQ:TCON - Get Rating) last released its quarterly earnings data on Wednesday, May 11th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.07). During the same period in the prior year, the company earned ($0.33) EPS. Analysts anticipate that TRACON Pharmaceuticals will post -1.24 EPS for the current year.

Insider Transactions at TRACON Pharmaceuticals

In related news, major shareholder Opaleye Management Inc. acquired 841,989 shares of the business's stock in a transaction dated Tuesday, June 21st. The shares were bought at an average price of $1.31 per share, with a total value of $1,103,005.59. Following the transaction, the insider now directly owns 3,776,589 shares of the company's stock, valued at $4,947,331.59. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have purchased 870,349 shares of company stock valued at $1,149,698 in the last 90 days. 3.09% of the stock is currently owned by corporate insiders.